BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 15342913)

  • 41. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
    Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
    [No Abstract]   [Full Text] [Related]  

  • 42. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
    Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW
    Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
    Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF
    Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M; Roehrl MH; Basar E; Wang JY
    Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
    Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
    Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.
    Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB
    Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
    Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
    Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
    Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
    Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.
    Liu TH; Oscherwitz J; Schnepp B; Jacobs J; Yu F; Cease KB; Johnson PR
    Mol Ther; 2009 Feb; 17(2):373-9. PubMed ID: 19002162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
    Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
    Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
    Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
    Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge.
    Kim NY; Chang DS; Kim Y; Kim CH; Hur GH; Yang JM; Shin S
    PLoS One; 2015; 10(10):e0139671. PubMed ID: 26430894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
    Lee DY; Chun JH; Ha HJ; Park J; Kim BS; Oh HB; Rhie GE
    FEMS Immunol Med Microbiol; 2009 Nov; 57(2):165-72. PubMed ID: 19732139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a novel multiepitope chimeric vaccine against anthrax.
    Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
    Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
    Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC; Köhler SM; Crafford J; van Heerden H; Beyer W
    Vet Immunol Immunopathol; 2016 Oct; 178():14-21. PubMed ID: 27496738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.
    Marcus H; Danieli R; Epstein E; Velan B; Shafferman A; Reuveny S
    Infect Immun; 2004 Jun; 72(6):3471-7. PubMed ID: 15155654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen.
    Peachman KK; Rao M; Alving CR; Burge R; Leppla SH; Rao VB; Matyas GR
    Infect Immun; 2006 Jan; 74(1):794-7. PubMed ID: 16369043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.